Physician profile
Colin Chan
NPI 1194710871
$4,357.56
in general payments reported to CMS, 2019-2025
30 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $661 · 2021: $685 · 2022: $567 · 2023: $652 · 2024: $717 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.86 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $797.11 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $636.05 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $352.49 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $251.87 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $244.34 | 2019-2025 | |
| Amgen INC. | $154.95 | 2019-2025 | Repatha, Otezla, Evenity |
| Allergan, INC. | $108.18 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.18 | 2020-2024 | Xifaxan |
| Eisai INC. | $99.13 | 2020-2024 | |
| Abbott Laboratories | $73.31 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.72 | 2020-2022 | |
| Astellas Pharma US INC | $60.16 | 2023-2024 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $54.79 | 2021 | |
| Ibsa Pharma INC. | $51.69 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $45.11 | 2020-2021 | |
| Lucid Diagnostics INC. | $42.29 | 2023 | |
| Jazz Pharmaceuticals INC. | $40.74 | 2021 | |
| Esperion Therapeutics, INC. | $34.56 | 2020 | |
| Idorsia Pharmaceuticals US INC | $32.01 | 2023-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $28.53 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.10 | 2019-2021 | |
| Antares Pharma, INC. | $22.69 | 2019 | |
| Alk-Abello, INC | $22.40 | 2024 | Grastek, Ragwitek, Odactra |
| Ethicon US, LLC | $22.04 | 2019 | |
| Merck Sharp & Dohme LLC | $18.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.08 | 2019 | |
| Gilead Sciences, INC. | $13.41 | 2019 | |
| Shire North American Group INC | $13.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.